| Timing has conspired to bring biopharmaceutical companies into the risk transfer arena just as the insurance market is at its least receptive to such risks. This article will highlight the driving factors and the change in management approach needed to negotiate this business hurdle, which will be new to many companies.When two independent industries both undergo radical and fundamental shifts in the make-up of their own revenue base, the results will be dramatic. Such is the current interface between the emerging biopharmaceutical industry and the retrenching insurance industry. |
